Biond Biologics develops biological therapies targeting immune evasion mechanisms in cancer patients, utilizing their proprietary INspire intracellular delivery platform for biologics. This approach enhances the efficacy of treatments by improving the delivery and effectiveness of therapeutic agents within cancer cells.
Funding
$36.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
DIFounders
Product
Problem
Many intracellular cancer targets are considered "undruggable" because conventional biologics lack the ability to efficiently penetrate cell membranes and access these targets within the cell. This limitation hinders the development of effective therapies against key drivers of cancer progression.
Solution
Biond Biologics is developing novel biological therapies for cancer by targeting previously inaccessible intracellular targets. Their INspire platform is designed to deliver protein-based biologics, such as antibodies and enzymes, directly into cells. The INspire technology utilizes a chemically modified carrier protein conjugated to a biologic payload, enabling cell internalization and endosomal escape. The carrier's modification includes a transiently masked positive charge, which facilitates targeted delivery to the tumor microenvironment and subsequent release of the payload within the cytoplasm, allowing the biologics to exert their functional activity on intracellular targets.
Target Audience
The primary target audience includes researchers and pharmaceutical companies focused on developing novel cancer therapies that target intracellular mechanisms.
Features
- Intracellular delivery of biologics, including antibodies, nanobodies, and enzymes
- Chemically modified carrier protein for efficient cell internalization
- Transient masking technology for targeted delivery to the tumor microenvironment (TME)
- Endosomal escape mechanism to release payloads into the cytoplasm
- Demonstrated delivery of agents targeting KRAS, BRAF, and HPV-E7
- Improved pharmacokinetics and biodistribution profiles through transient masking